ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2019. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,537 | -60.2% | 31,160 | -43.6% | 0.00% | – |
| Q2 2023 | $76,730 | -24.1% | 55,202 | -13.2% | 0.00% | – |
| Q1 2023 | $101,110 | -30.8% | 63,591 | +171.0% | 0.00% | – |
| Q4 2022 | $146,162 | +53.9% | 23,461 | +66.6% | 0.00% | – |
| Q3 2022 | $95,000 | -8.7% | 14,084 | -14.4% | 0.00% | – |
| Q2 2022 | $104,000 | +62.5% | 16,454 | +18.9% | 0.00% | – |
| Q1 2022 | $64,000 | -80.2% | 13,844 | -78.6% | 0.00% | – |
| Q4 2021 | $323,000 | -22.4% | 64,742 | +87.6% | 0.00% | – |
| Q3 2021 | $416,000 | -63.0% | 34,516 | -35.0% | 0.00% | – |
| Q2 2021 | $1,124,000 | -39.8% | 53,140 | -20.2% | 0.00% | -100.0% |
| Q1 2021 | $1,867,000 | +403.2% | 66,575 | +366.2% | 0.00% | – |
| Q4 2020 | $371,000 | -57.6% | 14,279 | -39.4% | 0.00% | – |
| Q3 2020 | $875,000 | -69.7% | 23,558 | -58.1% | 0.00% | -100.0% |
| Q2 2020 | $2,886,000 | -32.9% | 56,248 | -58.8% | 0.00% | -50.0% |
| Q1 2020 | $4,302,000 | +11.0% | 136,423 | +110.0% | 0.00% | +100.0% |
| Q4 2019 | $3,874,000 | +835.7% | 64,965 | +475.2% | 0.00% | – |
| Q3 2019 | $414,000 | -64.0% | 11,295 | -54.4% | 0.00% | – |
| Q2 2019 | $1,151,000 | +15.4% | 24,747 | -0.3% | 0.00% | – |
| Q1 2019 | $997,000 | -88.3% | 24,821 | -86.6% | 0.00% | -100.0% |
| Q4 2018 | $8,531,000 | +171.2% | 185,442 | +161.5% | 0.00% | +300.0% |
| Q3 2018 | $3,146,000 | +100.9% | 70,904 | +77.4% | 0.00% | 0.0% |
| Q2 2018 | $1,566,000 | -80.5% | 39,963 | -64.0% | 0.00% | -66.7% |
| Q1 2018 | $8,020,000 | +45.2% | 110,882 | +32.1% | 0.00% | +50.0% |
| Q4 2017 | $5,524,000 | +5.8% | 83,907 | -19.5% | 0.00% | 0.0% |
| Q3 2017 | $5,223,000 | -25.8% | 104,191 | -31.5% | 0.00% | -50.0% |
| Q2 2017 | $7,038,000 | +97.1% | 152,061 | +50.4% | 0.00% | +100.0% |
| Q1 2017 | $3,571,000 | +489.3% | 101,131 | +108.9% | 0.00% | – |
| Q4 2016 | $606,000 | -11.4% | 48,419 | -1.9% | 0.00% | – |
| Q3 2016 | $684,000 | +388.6% | 49,373 | +250.6% | 0.00% | – |
| Q2 2016 | $140,000 | -26.3% | 14,081 | +25.2% | 0.00% | – |
| Q1 2016 | $190,000 | -94.0% | 11,247 | -92.1% | 0.00% | -100.0% |
| Q4 2015 | $3,183,000 | +114.8% | 143,012 | +127.7% | 0.00% | +100.0% |
| Q3 2015 | $1,482,000 | +39.0% | 62,797 | +381.4% | 0.00% | 0.0% |
| Q2 2015 | $1,066,000 | +1737.9% | 13,045 | +1993.9% | 0.00% | – |
| Q1 2015 | $58,000 | -69.3% | 623 | -86.6% | 0.00% | – |
| Q4 2014 | $189,000 | – | 4,657 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |